版本:
中国

BRIEF-Novan presents safety data for SB204 program

April 27 Novan Inc

* Novan presents safety data for SB204 program

* Novan inc- in general, all doses of SB204 were well tolerated and not associated with any significant safety issues in these trials

* Novan inc - expects to report additional safety data from long-term safety trial, NI-AC303 in Q3 of this year

* Novan inc- NDA submission targeted in Q1 of 2018 for sb204

* Novan inc- intends to pursue a pre-submission meeting with fda to discuss entirety of SB204 development program in q3 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐